Hye-Ryun Kang

Hye-Ryun Kang

Auto-generated profile, based on publicly available information

Hye-Ryun Kang

Drug safety Center, Seoul National University Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Allergy
Verified
Journal Article
Open access
PDF file
MMMarcus Maurer
Marcus Maurer
MMMarkus Magerl
Markus Magerl
SBStephen Betschel
Stephen Betschel
WAWerner Aberer
Werner Aberer
IAIgnacio J. Ansotegui
Ignacio J. Ansotegui
TCTimothy Craig
Timothy Craig
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up‐to‐date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on‐demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast‐feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

1 October 2019 in Radiology
Verified
Journal Article
Closed access
MCMin Jae Cha
Min Jae Cha
DKDong Yoon Kang
Dong Yoon Kang
WLWhal Lee
Whal Lee
SYSoon Ho Yoon
Soon Ho Yoon
YCYoung Hun Choi
Young Hun Choi
HKHye-Ryun Kang
Hye-Ryun Kang
Family history and previous individual history of hypersensitivity reaction to iodinated contrast media were risk factors for new hypersensitivity occurrence. Premedication and change of iodinated ... Background Multicenter studies may be required for establishing guidelines for safe usage of iodinated contrast media (ICM). Purpose To identify the prevalence, patterns, risk factors, and preventi...

10 November 2020 in Allergy
Verified
Journal Article
Closed access
PDF file
MTMaría J Torres
María J Torres
ATAxel Trautmann
Axel Trautmann
IBIngrid Böhm
Ingrid Böhm
KSKathrin Scherer
Kathrin Scherer
ABAnnick Barbaud
Annick Barbaud
KBKnut Brockkow
Knut Brockkow

11 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMin-Suk Yang
Min-Suk Yang
JLJin Yong Lee
Jin Yong Lee
JKJayeun Kim
Jayeun Kim
GKGun-Woo Kim
Gun-Woo Kim
BKByung-Keun Kim
Byung-Keun Kim
HKHye-Ryun Kang
Hye-Ryun Kang
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases; however, it is hard to estimate their incidence due to the rarity of these diseases. We evaluated the incidence of SJS and TEN using a nationwide administrative database. We used a national medical insurance review system (Health Insurance Review and Assessment) database which contained the claim data of the entire nation from 2009 to 2013 to estimate the accurate incidence of SJS and TEN in Korea. The diagnostic codes of L511 (SJS) or L512 (TEN) from the International Classification of Diseases-10th revision were used to define the target study population. We also retrospectively followed up a 2011 SJS and TEN cohort for 24 months in order to assess the in-hospital mortality, related complications and total claims cost due to SJS and TEN. A total of 1,167 (938 SJS and 229 TEN) cases were newly diagnosed from 2010 to 2013. The age- and sex-standardized annual incidences estimated in this study were 3.96 to 5.03 in SJS and 0.94 to 1.45 in TEN per million. There was no significant change in annual incidence throughout the study periods. When analyzed by 10-year age groups, the annual incidence was the lowest in group 20–29 years and the highest in group 70 for both SJS and TEN. Based on the 2011 cohort analysis, the in-hospital mortality were 5.7 and 15.1% for SJS and TEN, respectively. The mortality increased with age, particularly, after 40 years of age. Among the complications related with SJS or TEN, ocular sequelae was the most common (43.1 and 43.4% of SJS and TEN patients, respectively) followed by urethral sequelae (5.7 and 9.4% of SJS and TEN patients, respectively). Overall, our data suggest that SJS, and TEN are infrequent but constantly arise throughout the years.

6 February 2026 in Allergy
Verified
Journal Article
Open access
Torsten ZuberbierTorsten Zuberbier
Torsten Zuberbier
ZAZainab AbdulHameed Ansari
Zainab AbdulHameed Ansari
ALAmir H. Abdul Latiff
Amir H. Abdul Latiff
MAM. M. Abuzakouk
M. M. Abuzakouk
MJMaria Socorro Agcaoili‐De Jesus
Maria Socorro Agcaoili‐De Jesus
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.

14 December 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
HPHye Jung Park
Hye Jung Park
JPJung-Won Park
Jung-Won Park
MYMin-Suk Yang
Min-Suk Yang
MKMi-Yeong Kim
Mi-Yeong Kim
SKSae-Hoon Kim
Sae-Hoon Kim
HKHye-Ryun Kang
Hye-Ryun Kang